154 related articles for article (PubMed ID: 19799193)
1. [Clinical implications of urine matrix metalloproteinases and their inhibitors in patients with chronic glomerulonephritis].
Li OA; Bobkova IN; Kozlovckaia LV
Ter Arkh; 2009; 81(8):10-4. PubMed ID: 19799193
[TBL] [Abstract][Full Text] [Related]
2. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis].
Bobkova IN; Kozlovskaia LV; Rameeva AS; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2007; 79(6):10-5. PubMed ID: 17684960
[TBL] [Abstract][Full Text] [Related]
3. [Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis].
Smyr KV; Shcherbak AV; Kozlovskaia LV; Sokolova IA; Bobkova IN; Podorol'skaia LV
Ter Arkh; 2010; 82(1):47-51. PubMed ID: 20364701
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
5. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Babjuk M
Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
[No Abstract] [Full Text] [Related]
7. [Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis].
Tenderenda E; Zoch-Zwierz W; Wasilewska A; Porowski T; Taranta-Janusz K; Kołodziejczyk Z; Michaluk-Skutnik J
Pol Merkur Lekarski; 2009 Jul; 27(157):10-3. PubMed ID: 19650421
[TBL] [Abstract][Full Text] [Related]
8. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.
Mazanowska O; Kamińska D; Krajewska M; Zabińska M; Kopeć W; Boratyńska M; Chudoba P; Patrzalek D; Klinger M
Transplant Proc; 2011 Oct; 43(8):3000-3. PubMed ID: 21996210
[TBL] [Abstract][Full Text] [Related]
9. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.
Sanders JS; Huitema MG; Hanemaaijer R; van Goor H; Kallenberg CG; Stegeman CA
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1927-34. PubMed ID: 17898039
[TBL] [Abstract][Full Text] [Related]
10. [Urinary fibronectin as an indicator of kidney fibrosis in nephritis].
Kozlovskaia LV; Bobkova IN; Varshavskiĭ VA; Proskurneva EP; Miroshnichenko NG; Chebotareva NV; Mukhin NA
Ter Arkh; 1999; 71(6):34-8. PubMed ID: 10420453
[TBL] [Abstract][Full Text] [Related]
11. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
12. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
[TBL] [Abstract][Full Text] [Related]
15. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
16. [Role of IL-8 and defensins in pathogenesis of chronic glomerulonephritis and pyelonephritis].
Rebenok AZh; Tikhonov II; Chizh AS
Ter Arkh; 1999; 71(8):62-7. PubMed ID: 10515041
[TBL] [Abstract][Full Text] [Related]
17. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
[TBL] [Abstract][Full Text] [Related]
18. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
19. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
20. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]